Ming et al. [43] also reported the inhibitory action of corilagin on hepatocellular carcinoma cells (HCC) at the G2/M phase by upregulating p53 and p21, and downregulating cyclin B1, cdc 2, and pAKT. This evidence concerns the gene TP53 and hepatocellular carcinoma.